{"name":"Ariston Pharmaceuticals, Inc.","slug":"ariston-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"Ariston Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for gastrointestinal disorders. The company's lead candidate, AST-726, is currently in Phase 2 trials for multiple indications.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AST-726 High dose","genericName":"AST-726 High dose","slug":"ast-726-high-dose","indication":"Other","status":"phase_2"},{"name":"AST-726 Low dose","genericName":"AST-726 Low dose","slug":"ast-726-low-dose","indication":"Phase 2 clinical trials for AST-726 are ongoing, but specific indications have not been disclosed.","status":"phase_2"}]}],"pipeline":[{"name":"AST-726 High dose","genericName":"AST-726 High dose","slug":"ast-726-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AST-726 Low dose","genericName":"AST-726 Low dose","slug":"ast-726-low-dose","phase":"phase_2","mechanism":"AST-726 is a low-dose drug that targets a specific molecular pathway.","indications":["Phase 2 clinical trials for AST-726 are ongoing, but specific indications have not been disclosed."],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}